Inari Medical, Inc. Stock Price, News & Analysis

Inari Medical, Inc. (NASDAQ: NARI) announced the upcoming enrollment of the PEERLESS trial, a pivotal randomized controlled trial comparing the FlowTriever System against catheter-directed thrombolysis for treating intermediate-high risk pulmonary embolism. The trial will include up to 700 patients at 60 centers across the U.S. and Europe. Key outcomes will focus on mortality, major bleeding events, and ICU stay duration. The PEERLESS trial aims to provide critical data to reshape treatment guidelines for venous thromboembolism.

Inari Medical, Inc. (NASDAQ: NARI) has appointed Mr. Dana G. Mead, Jr. to its board of directors, where he will also serve on the Compensation Committee. His extensive experience in leading high-growth medical technology companies is expected to be crucial as Inari advances its mission to treat venous thromboembolism. Mead's prior roles include President and CEO of HeartFlow, and he has held leadership positions at Beaver-Visitec and Guidant Corporation. Inari is known for its innovative catheter-based thrombectomy devices aimed at improving patient outcomes in venous diseases.

Inari Medical (NASDAQ: NARI) has appointed Dr. Victor F. Tapson as VP of Medical Affairs. Dr. Tapson brings extensive expertise in pulmonary diseases, particularly in pulmonary embolism and hypertension, and has authored over 200 peer-reviewed articles. His previous roles include establishing the first Pulmonary Embolism Response Team at Cedars-Sinai Medical Center and leading innovative programs at Duke University. Dr. Tapson's leadership is expected to enhance Inari's mission to improve venous disease treatments, specifically targeting venous thromboembolism (VTE).

Inari Medical, Inc. (NASDAQ: NARI), a medical device company dedicated to treating venous diseases, announced its participation in two investor conferences. The 2021 Virtual Wells Fargo Healthcare Conference is set for September 9, 2021, at 4:00 p.m. ET, followed by the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 1:15 p.m. ET. A live webcast of both presentations will be available on the company’s website. Inari Medical specializes in innovative catheter-based devices for treating deep vein thrombosis and pulmonary embolism.

Inari Medical (NASDAQ: NARI) announced its second-quarter financial results for 2021, reporting a record revenue of $63.5 million, an 11% increase sequentially, and a remarkable 150% year-over-year growth. The company obtained FDA clearance for FlowSaver, enhancing their treatment capabilities. Gross profit surged to $58.6 million with a gross margin of 92.4%. Operating expenses rose to $54.5 million, largely due to personnel growth. Inari expects 2021 revenue between $250 million and $255 million, raising previous guidance amid ongoing COVID-19 challenges.

Inari Medical, Inc. (NASDAQ: NARI), a medical device company specializing in venous diseases, announced its participation in the Canaccord Genuity 41st Annual Growth Conference. The presentation is scheduled for August 12, 2021, at 10:30 a.m. Eastern Time. Inari focuses on innovative catheter-based mechanical thrombectomy devices, such as the ClotTriever and FlowTriever systems, designed to treat deep vein thrombosis and pulmonary embolism effectively. Both devices have received FDA 510(k) clearance and CE Mark approval, emphasizing the company’s commitment to transforming patient care in venous thromboembolism.

Inari Medical, Inc. (NASDAQ: NARI) will announce its second quarter financial results on August 10, 2021. A conference call and webcast will follow at 1:30 p.m. PT to discuss the results and updates. Inari is known for its innovative medical devices aimed at treating venous diseases, including the ClotTriever and FlowTriever systems, both approved by the FDA and CE Mark for deep vein thrombosis and pulmonary embolism treatments, respectively. The company's focus remains on transforming patient care in venous thromboembolism.

Inari Medical, Inc. (NASDAQ: NARI) announced the appointment of Ms. Rebecca Chambers to its board of directors on June 22, 2021. Chambers, the CFO of Outset Medical, brings over a decade of healthcare leadership experience, including significant roles in investor relations for publicly traded companies. CEO Bill Hoffman stated that her expertise will be crucial as Inari continues to innovate in the venous thromboembolism treatment space. Inari develops minimally-invasive catheter-based devices for treating venous diseases, with products approved by the FDA and CE Mark.

Inari Medical, Inc. (NASDAQ: NARI) announced positive interim results from the ClotTriever Outcomes Registry (CLOUT) for the first 250 deep vein thrombosis (DVT) patients. The ClotTriever successfully removed 100% of blood clots in most cases without thrombolytic drugs, resulting in a median procedure time of 28 minutes and a modest blood loss of 50ml. This registry, the largest of its kind for mechanical thrombectomy treatment, highlights the effectiveness of ClotTriever, demonstrating a commitment to improving venous disease treatment.